Fig. 4

DRα1-mMOG-35-55 treatment of permanent MCAO: a Four daily 100 μg DRα1-mMOG-35-55 treatments significantly reduced infarct volumes and b infiltration of CD4⁺ and c CD8⁺ T cells and d increased numbers of CD206⁺Iba1⁺ microglia/macrophages into the ischemic hemisphere of C57BL/6 male mice 96 h after induction of dMCAO (*p < 0.05). Mice treated with DRα1-mMOG-35-55 or vehicle were evaluated for sensorimotor functions 10 days after dMCAO and demonstrated significant improvement in (e) Rotarod test, (f) Adhesive removal test and (g) Modified Garcia scores (total neurologic assessment) that included body proprioception, vibrissae touch (NS), limb symmetry, lateral turning, and forelimb walking. NS no significance. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Reprinted by permission from RightsLink: Springer, Translational Stroke Research, DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury, Wang et al., copyright 2017